Xiaohua Hong

ORCID: 0000-0002-4356-7002
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Head and Neck Cancer Studies
  • Cancer Immunotherapy and Biomarkers
  • Cholangiocarcinoma and Gallbladder Cancer Studies
  • Lung Cancer Treatments and Mutations
  • Cancer, Lipids, and Metabolism
  • Colorectal Cancer Treatments and Studies
  • RNA modifications and cancer
  • Ferroptosis and cancer prognosis
  • Cancer Genomics and Diagnostics
  • Inflammatory Biomarkers in Disease Prognosis
  • Ear and Head Tumors
  • Salivary Gland Tumors Diagnosis and Treatment
  • Head and Neck Surgical Oncology

Wuhan Union Hospital
2023

Union Hospital
2022

Huazhong University of Science and Technology
2022

Abstract Purpose: This study aimed to assess the antitumor activity and safety of neoadjuvant chemotherapy combined with PD-1 inhibitor camrelizumab in patients locally advanced head neck squamous cell carcinoma (HNSCC). Patients Methods: In this single-center, single-arm, phase 2 trial, resectable stage III–IVB HNSCC received [albumin-bound paclitaxel 260 mg/m2 (or docetaxel 75 mg/m2) plus cisplatin mg/m2] 200 mg on day 1 each 21-day cycle for three cycles, followed by surgery, adjuvant...

10.1158/1078-0432.ccr-22-0666 article EN cc-by-nc-nd Clinical Cancer Research 2022-06-29

Background The major aim of this Bayesian network analysis was to determine the optimal treatment strategy for locoregionally advanced nasopharyngeal carcinoma (LANPC). Method We systematically searched databases and extracted data from randomized clinical trials involving LANPC patients randomly assigned receive induction chemotherapy followed by concurrent chemoradiotherapy (IC+CCRT), CCRT adjuvant (CCRT+AC), or CCRT. Results In analysis, IC+CCRT significantly better than alone 5-year FFS...

10.1371/journal.pone.0265551 article EN cc-by PLoS ONE 2022-03-18

We used bibliometric methods to assess the global scientific output on IRAEs for colorectal cancer and explore current status trends in field over last three decades.Studies immune-related adverse events published from 1996 2022 were retrieved Web of Science. For quantitative qualitative assessments publication outputs author contributions, R bibliometrix package was used. VOSviewer construct networks based co-authorship countries/institutions/authors, co-citation analysis...

10.3389/fonc.2022.1024321 article EN cc-by Frontiers in Oncology 2022-10-27

Cuproptosis, a recently found kind of programmed cell death, has been linked to tumor development, prognosis, and therapeutic response. The roles cuproptosis-related genes (CRG) in the microenvironment (TME) are, nevertheless, unknown. We evaluated alterations CRG assessed related expression patterns 1445 lung cancer (LC) samples from three separate datasets, analyzing genetic, transcriptional domains. discovered two molecular subtypes that various were connected with patient clinical...

10.1155/2022/7406636 article EN cc-by BioMed Research International 2022-01-01

<title>Abstract</title> <bold>Background</bold>The addition of immune checkpoint inhibitors (ICIs) to platinum-based chemotherapy has shown promising antitumor activity in patients with recurrent or metastatic nasopharyngeal carcinoma (RM-NPC), who have poor survival outcomes. We therefore compared the efficacy and adverse events taxanes-cisplatin (TP) camrelizumab plus TP RM-NPC.<bold>Materials methods</bold>In this retrospective study, we collected medical records 194 RM-NPC between June...

10.21203/rs.3.rs-2825185/v1 preprint EN cc-by Research Square (Research Square) 2023-04-19
Coming Soon ...